Scientist.com and Evotec Partner to Accelerate Drug Discovery and Development
Scientist.com, the leading research platform for the pharmaceutical industry, has announced a new partnership with Evotec SE, a leading drug discovery and development company. Through this collaboration, Evotec’s comprehensive suite of R&D services, spanning the entire drug discovery and development process, will now be available to registered users on Scientist.com’s award-winning digital marketplace.
"At Evotec, our mission is to deliver high-quality, efficient, and innovative drug discovery services that advance the work of researchers developing novel treatments," said Dr. Matthias Evers, Chief Business Officer of Evotec. "By partnering with Scientist.com, we can expand our reach and empower more scientists in their efforts to bring new therapies to market."
Evotec offers the Scientist.com research community access to an extensive array of proprietary technologies, including cutting-edge in vitro and in vivo pharmacology, high-throughput screening, and a comprehensive suite of next-generation sequencing tools. Through the marketplace, clients can simplify the procurement process and collaborate with Evotec’s expert team to design and implement customized R&D projects. This partnership allows researchers to tap into Evotec’s deep expertise across various therapeutic areas—such as neuroscience, metabolic diseases, oncology, and infectious diseases—significantly accelerating the journey from concept to clinical reality. Evotec’s offering on Scientist.com also includes predictive toxicology and ADME-PK services through Cyprotex – an Evotec Company.
"Evotec's unwavering commitment to quality and innovation and the breadth of its offerings aligns perfectly with our mission to connect scientists with the tools and expertise they need to more rapidly advance their drug research," said Kevin Lustig, PhD, Founder and CEO of Scientist.com. "Through Scientist.com, virtually any research experiment in any therapeutic area can now be seamlessly designed, ordered, and executed."
About Scientist.com
Scientist.com is the leading AI-enabled digital research platform for the life science industry. The platform simplifies drug research, saving time and money, providing access to the latest innovative tools and technologies, and ensuring that researchers and suppliers adhere to internal and external compliance requirements. Scientist.com operates private research platforms for most of the world’s major pharmaceutical companies, over 100 biotechnology companies and the US National Institutes of Health (NIH). To learn more, visit Scientist.com.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909283991/en/
Contacts
Scientist.com
Sean Preci
+1 877-644-3044
marketing@scientist.com
Evotec SE
Gabriele Hansen
+49 (0)160 7164389
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder
+49 (0)151 40704843
Hinnerk.Rohwedder@evotec.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results13.6.2025 16:14:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. “Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,” noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compared to $63.1 million at April 30, 2024. We feel encouraged with the level of backlog we have obtained, which remains more than double the level of reported backlog at the end of the first quarter last year,” Mr. Sagr continued. “Our first quarter results represent unprecedented perfor
Capcom’s Devil May Cry 5 Sales Top 10 Million Units!13.6.2025 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide cumulative sales of Devil May Cry 5 havesurpassed 10 million units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613788747/en/ Devil May Cry 5 logo In Devil May Cry 5, players can enjoy thrilling, high-speed gameplay, stylish action, and beautiful graphics, depicted with intricate realism thanks to Capcom’s proprietary RE ENGINE. The title has garnered strong support from users due to its exceptional gameplay experience, leading to expanded sales as a catalog title since its release. Capcom provided an even more advanced story and action elements in the game with the addition of a new playable character, and more recently, on April 3, 2025, the company released the new Devil May Cry animated series on Netflix, in line with the company’s Single Content Multiple Usage strategy. The animated series has garnered critical acclaim from around the world, and with mor
realme Summer Party: a Major Event and an Exclusive Collaboration with TikTok13.6.2025 15:59:00 EEST | Press release
realme, one of the world's leading smartphone brands, held a summer festival on June 6 and 7 at the foot of the Eiffel Tower with fun activities. Visitors could try their hand at ring throwing, immortalize their moments at the Photobooth van, or leave with exclusive gifts. Each participant received a voucher to exchange for a prize in the dedicated area for a successful festive experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612984325/en/ Live photo from realme Summer Party and the newly launched GT 7 Dream Edition A festive event at the foot of the Eiffel Tower The event was a great success, thanks to the engagement of participants on-site and through social media. Many visitors shared photos and videos, creating a dynamic and friendly atmosphere, amplified by the realme community. An exclusive collaboration between realme and TikTok This collaboration between realme and TikTok extends beyond this event. Indee
Take It Slow: Why Ireland Is the Perfect Destination for the ‘Unrushed’ Traveller13.6.2025 15:30:00 EEST | Press release
Tourism Ireland--In a world that’s always rushing, Ireland is extending a gentle invitation: take your time. With its winding coastal trails, soul-soothing landscapes, and deep-rooted traditions, Ireland is emerging as one of Europe’s most natural fits for slow tourism — a growing global travel trend focused on deeper, more meaningful experiences over fast-paced itineraries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612345730/en/ Cycling on greenway, County Waterford From misty mornings in the Burren to long afternoons along the Wild Atlantic Way, Ireland rewards those who slow down. Whether it’s connecting with local craftspeople, foraging along the coast, lingering over storytelling sessions in a pub, or staying in family-run farmhouses — the country’s charm reveals itself not in a rush, but in the details. What is ‘Slow Tourism’? Slow tourism encourages travellers to engage more fully with a destination, spending
Technology Reply earns Oracle Service Expertise in Artificial Intelligence for the Western Europe region13.6.2025 11:00:00 EEST | Press release
Technology Reply, a company of the Reply Group specialising in the design of solutions based on Oracle technologies, has been presented with the Oracle Service Expertise in Artificial Intelligence for the Western Europe region, further consolidating its position as a key partner for AI projects on Oracle Cloud Infrastructure (OCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613439196/en/ Thanks to this certification, Technology Reply strengthens its role as a technology partner for companies seeking to enhance their enterprise applications, improve user interaction, and accelerate decision-making processes through artificial intelligence and Oracle technologies. The Service Expertise certification is in recognition of Technology Reply’s technical and design capabilities in building solutions based on OCI’s AI services, including the use of pre-trained models, chatbot development, custom model creation, and the adoptio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom